Abstract:RRP is caused by HPV infection of the aerodigestive tract that significantly impacts quality‐of‐life including the ability to communicate and breathe. This study aims to determine whether rationale exists for combination therapeutic approaches using VEGF inhibitors and/or immune checkpoint blockade. Our analysis shows that RRP tissue shows elevated levels of multiple immune check point targets and VEGFR3, with varied patterns unique to each papilloma patient. Some of these immune checkpoint markers already have novel immunotherapies available or in development, providing molecular rationale to offer these systemic treatments to selected patients affected by RRP alongside VEGF inhibitors. Objectives Recurrent respiratory papillomatosis (RRP) is caused by human papilloma virus (HPV) infection of the aerodigestive tract that significantly impacts quality‐of‐life including the ability to communicate and breathe. Treatment was traditionally limited to serial ablative procedures in the O.R. with possible local adjuvant therapy, but new systemic therapies, such as Vascular endothelial growth factor (VEGF) inhibitors, are showing significant promise. This study aims to determine whether rationale exists for combination therapeutic approaches using VEGF inhibitors and/or immune checkpoint blockade. Methods Using fresh specimens from the O.R., we performed flow cytometry on papilloma, normal adjacent tissue, and blood. Papilloma and surrounding tissue were examined for expression of PD‐L1, PD‐L2, Galectin‐9, VEGFR2, and VEGFR3. CD8+ and CD4+ T cells were assayed for expression of PD‐1, TIGIT, LAG3, and TIM3. Results Our data shows that papilloma tissue exhibits significantly higher levels of PD‐L1 and PD‐L2 compared to adjacent tissue. Elevated levels of the VEGF receptor VEGFR3 were also observed in papilloma tissue. When examining T cells within the papilloma, elevated PD‐1 and TIGIT expression was observed on CD8+ T cells, while levels of PD‐1, TIGIT, and TIM3 were elevated on CD4+ T cells compared to PBMCs. Heterogenous marker expression was observed between individuals. Conclusions Our analysis shows that RRP tissue shows elevated levels of multiple immune check point targets and VEGFR3, with varied patterns unique to each papilloma patient. Some of these immune checkpoint markers already have novel immunotherapies available or in development, providing molecular rationale to offer these systemic treatments to selected patients affected by RRP alongside VEGF inhibitors. Laryngoscope, 2024

Systemic bevacizumab for treatment of recurrent respiratory papillomatosis

Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Institution's Experience

Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review

Adjuvant Intralesional Bevacizumab in Pediatric and Adult Populations With Recurrent Respiratory Papillomatosis: A Systematic Review

Successful Bevacizumab Therapy in a 25-Year-Old Patient with Recurrent Respiratory Papillomatosis

Quantifying Bevacizumab Efficacy in Recurrent Respiratory Papillomatosis

[Advances in the use of bevacizumab for the treatment of respiratory papilloma]

Healthcare Spending and Systemic Bevacizumab for Recurrent Respiratory Papillomatosis

Sublesional Bevacizumab Injection for Recurrent Respiratory Papillomatosis: Evaluation of Utility in a Typical Clinical Practice

Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis

Effectiveness of combined approach to recurrent respiratory papillomatosis (RRP)

VEGF as a Key Actor in Recurrent Respiratory Papillomatosis: A Narrative Review

Current Practice, Safety and Efficacy of Interventions for Recurrent Respiratory Papillomatosis: Evidence From a UK Registry

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis

Experimental Research on the Therapeutic Effect of MMR Vaccine to Juvenile-Onset Recurrent Respiratory Papillomatosis.

Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes

The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy

Topical measles-mumps-rubella vaccine in the treatment of recurrent respiratory papillomatosis: results of a preliminary randomized, controlled trial.

Therapeutic effect of Measles Mumps Rubella vaccine on juvenile onset recurrent respiratory papillomatosis

Safety and Efficacy of Bevacizumab Combined with R-CHOP Regimen in Seven Chinese Patients with Untreated Diffuse Large B-cell Lymphoma

Application of microdebritor in the treatment of the juvenile onset recurrent respiratory papillomatosis]